BMO Capital initiates coverage on Teva Pharma (NYSE: TEVA) with a Outperform rating and a price target of $80.00.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $72.00 yesterday.

New Coverage

Canaccord Genuity Raises Price Target on Teva Pharma (TEVA) Following Announced Acquisition of Allergan Generics July 28, 2015 9:23 AM Leerink Partners Raises Price Target to $84 on Teva Pharma (TEVA) Following Call with CFO July 28, 2015 8:12 AM Teva Pharma (TEVA) PT Bumped to $75 at Piper JaffrayJuly 28, 2015 7:39 AM Teva Pharma (TEVA) Prelim. Q2 Revenue, EPS Outpace ViewsJuly 27, 2015 6:14 AM Teva Pharma (TEVA) to Acquire Allergan Genetics (AGN) in $40.5B Cash and Stock DealJuly 27, 2015 6:03 AM Teva Reports Preliminary Second Quarter 2015 ResultsJuly 27, 2015 4:47 AM Teva Withdraws Proposal to Acquire MylanJuly 27, 2015 4:31 AM Teva to Acquire Allergan Generics for $40.5 Billion Creating a Transformative Generics and Specialty Company Well Positioned to Win in Global HealthcareJuly 27, 2015 4:30 AM Teva Pharma (TEVA) Nears Deal to Acquire Allergan's (AGN) Generic-Drug BusinessJuly 26, 2015 5:23 PM